samedan logo
 
 
spacer
home > epc > summer 2007 > cost-managed compliance
PUBLICATIONS
European Pharmaceutical Contractor

Cost-Managed Compliance

Carl Turner at Compliance Control reviews the importance of regulatory compliance and suggests methods to keep costs down

Information is the lifeblood of the modern organisation. Management of information is important, but effective cost management is essential. Primarily, businesses exist to make a profit and provide returns to investors or owners. But, with heavily regulated industries such as the pharmaceutical industry, it is sometimes difficult to gain total support within an organisation for compliance and validation of companies’ computerised or automated systems. The perception is that this is a cost to the business and provides very little business benefit, even though companies understand the regulatory requirements to some degree.

Regulatory authorities have taken enforcement action as a result of a failure to comply with the regulatory requirement to validate and maintain systems in a compliant manner. Companies can ensure compliance by initiating various planned activities – but at what cost? And exactly how much ‘compliance or validation’ is actually needed and in what timeframe? Furthermore, if you are involved with gaining or maintaining support for such activities, how do you convince directors or senior management within an organisation that serious funding is required to ensure compliance is built into processes in the first place? Large, medium and small companies within the EU and beyond are faced with similar issues, and several industry led guideline documents from professional organisations as well as regulatory authorities exist, but where do you actually start and how do you manage control more effectively?


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
4
     

There are no comments in regards to this article.

spacer
Carl Turner has been involved in information technology for over 28 years. He has spent over 12 years in the pharmaceutical and life science industry and has been involved in the production of industry guidelines such as the Global Information Systems Control and Compliance. Carl has worked on countless projects involving compliance throughout Europe, the US, Africa and Asia, covering large, medium and small companies.
spacer
Carl Turner
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement